Cargando…

Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis

BACKGROUND: The aim of this study is to develop a novel in situ gel of tacrolimus-loaded SLNs (solid lipid nanoparticles) for ocular drug delivery. METHODS: The optimal formulation was characterized by surface morphology, particle size, zeta potential, entrapment efficiency, drug loading and in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kexin, Hu, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811375/
https://www.ncbi.nlm.nih.gov/pubmed/33469266
http://dx.doi.org/10.2147/DDDT.S287721
_version_ 1783637483743870976
author Sun, Kexin
Hu, Ke
author_facet Sun, Kexin
Hu, Ke
author_sort Sun, Kexin
collection PubMed
description BACKGROUND: The aim of this study is to develop a novel in situ gel of tacrolimus-loaded SLNs (solid lipid nanoparticles) for ocular drug delivery. METHODS: The optimal formulation was characterized by surface morphology, particle size, zeta potential, entrapment efficiency, drug loading and in vitro release behavior. In vivo studies were also conducted to evaluate the pharmacokinetic and pharmacodynamic results. RESULTS: In this study, TAC-SLNs ISG were prepared using homogenization followed by probe sonication method. The average particle size of TAC-SLNs ISG was observed to be 122.3±4.3 nm. Compared with TAC-SLNs, in situ gel did not increase particle size, and there was no significant difference between them. The results of viscosity measurement showed that TAC SLNs-ISG were typical of pseudo plastic systems and showed a marked increase in viscosity as temperature increased and ultimately formed a rigid gel (32°C). In vitro and in vivo studies illustrated the sustained release model of the drug from TAC-SLNs ISG. Animal model showed that TAC-SLNs ISG had good pharmacodynamics when compared with eye drops and SLNs. CONCLUSION: Our results demonstrated that TAC SLNs-ISG had the potential for being an ideal ocular drug delivery system.
format Online
Article
Text
id pubmed-7811375
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78113752021-01-18 Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis Sun, Kexin Hu, Ke Drug Des Devel Ther Original Research BACKGROUND: The aim of this study is to develop a novel in situ gel of tacrolimus-loaded SLNs (solid lipid nanoparticles) for ocular drug delivery. METHODS: The optimal formulation was characterized by surface morphology, particle size, zeta potential, entrapment efficiency, drug loading and in vitro release behavior. In vivo studies were also conducted to evaluate the pharmacokinetic and pharmacodynamic results. RESULTS: In this study, TAC-SLNs ISG were prepared using homogenization followed by probe sonication method. The average particle size of TAC-SLNs ISG was observed to be 122.3±4.3 nm. Compared with TAC-SLNs, in situ gel did not increase particle size, and there was no significant difference between them. The results of viscosity measurement showed that TAC SLNs-ISG were typical of pseudo plastic systems and showed a marked increase in viscosity as temperature increased and ultimately formed a rigid gel (32°C). In vitro and in vivo studies illustrated the sustained release model of the drug from TAC-SLNs ISG. Animal model showed that TAC-SLNs ISG had good pharmacodynamics when compared with eye drops and SLNs. CONCLUSION: Our results demonstrated that TAC SLNs-ISG had the potential for being an ideal ocular drug delivery system. Dove 2021-01-12 /pmc/articles/PMC7811375/ /pubmed/33469266 http://dx.doi.org/10.2147/DDDT.S287721 Text en © 2021 Sun and Hu. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Kexin
Hu, Ke
Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title_full Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title_fullStr Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title_full_unstemmed Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title_short Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis
title_sort preparation and characterization of tacrolimus-loaded slns in situ gel for ocular drug delivery for the treatment of immune conjunctivitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811375/
https://www.ncbi.nlm.nih.gov/pubmed/33469266
http://dx.doi.org/10.2147/DDDT.S287721
work_keys_str_mv AT sunkexin preparationandcharacterizationoftacrolimusloadedslnsinsitugelforoculardrugdeliveryforthetreatmentofimmuneconjunctivitis
AT huke preparationandcharacterizationoftacrolimusloadedslnsinsitugelforoculardrugdeliveryforthetreatmentofimmuneconjunctivitis